+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 34 Actively Recruiting clinical trials

L

Actively Recruiting

This research evaluates the long-term safety and tolerability of LB-102 in adults with stable schizophrenia who are experiencing inadequate response or side effects from their current antipsychotic medications, or who have completed earlier LB-102 studies. It is a Phase 3, open-label, multicenter study focusing on patients who wish to change medications or continue treatment with LB-102. Participants receive LB-102 with flexible dosing ranging from 50 mg to 100 mg. The study is open-label, meaning all participants receive the study drug without a placebo comparison. The treatment period lasts 52 weeks, during which researchers monitor safety and tolerability. Throughout the study, participants are closely assessed for adverse events and treatment-emergent events to evaluate safety. Effectiveness is also measured using the Positive and Negative Syndrome Scale PANSS. The study duration is one year, during which participants undergo regular evaluations to track their response and monitor any side effects.

Age: 18Years - 65YearsAll GendersPhase 3
23 locations
O

Actively Recruiting

Researchers are evaluating the long-term safety, tolerability, and effectiveness of ML-007C-MA in adults with schizophrenia. This open-label Phase 2 study includes participants who have recently completed a previous related study or new participants enrolling directly. The study focuses on adults aged 18 to 65 diagnosed with schizophrenia who may benefit from ongoing pharmacotherapy and can maintain outpatient care. Participants will receive ML-007C-MA dosed at 2103 mg twice daily for up to 52 weeks. This single-group study does not involve placebo and assesses the medications impact over the treatment period. The study allows for continuous monitoring and adjustment based on the participants response and tolerability. During the study, participants will be involved in regular assessments to monitor safety and tolerability from the initial dose through the entire treatment period. Evaluations include clinical interviews, physical exams, ECGs, and laboratory tests to track any adverse effects or changes in health status. Researchers will also gather information from a reliable informant to support assessments. The total participation duration can be up to one year.

Age: 18Years - 65YearsAll GendersPhase 2
45 locations
E

Actively Recruiting

Researchers are evaluating the safety and effectiveness of a combined treatment using KarXT and KarX-EC in adults aged 55 to 90 years who experience agitation related to Alzheimers Disease. This Phase 3, randomized, double-blind, placebo-controlled study is sponsored by Bristol-Myers Squibb and aims to address agitation symptoms in this population by comparing the study drugs against placebo. Participants have a confirmed Alzheimers diagnosis and agitation symptoms as defined by recognized criteria. Participants receive either the combined drugs KarXT and KarX-EC or a placebo, with doses given on specified days. The study is designed with parallel groups and maintains blinding to ensure unbiased results. This treatment period lasts 14 weeks, during which the effects on agitation and related symptoms are closely monitored. During the trial, participants and their caregivers attend regular visits to assess changes in agitation using established tools like the Cohen-Mansfield Agitation Inventory-International Psychogeriatric Association CMAI-IPA and other scales. Safety is monitored through adverse event tracking, physical exams, laboratory tests, vital signs, and electrocardiograms. The study also evaluates cognitive and behavioral changes up to 18 weeks, with caregivers playing a key role in reporting participant status and medication adherence.

Age: 55Years - 90YearsAll GendersPhase 3
162 locations
S

Actively Recruiting

Researchers are evaluating the efficacy and safety of brenipatide, given alongside standard of care, compared with a placebo plus standard of care, in delaying the worsening of symptoms in adults with bipolar disorder. This phase 2, randomized, double-blind study aims to better understand how brenipatide might help manage bipolar disorder symptoms over time. Participants receive either one of two doses of brenipatide or a placebo, both administered by subcutaneous injection, combined with their standard bipolar disorder treatment. The study includes three main periods a screening period lasting about one month, a treatment period lasting at least six months, and a follow-up period of about two months. Study participation may be shortened if symptoms worsen or if the participant chooses to withdraw. During the study, participants are asked to self-inject the study medication, keep electronic and paper diaries, and complete questionnaires. Researchers will monitor outcomes such as time to relapse, changes in disability, depression and mania scores, quality of life, patient impressions, body weight changes, and treatment-related antibody development. Safety and effectiveness measures will be collected throughout treatment and follow-up, with total participation lasting around nine months or less depending on individual circumstances.

Age: 18Years - 75YearsAll GendersPhase 2
87 locations
E

Actively Recruiting

Researchers are evaluating the safety and effectiveness of brenipatide combined with standard treatment compared to placebo with standard treatment in adults with schizophrenia. This phase 2 study aims to understand how brenipatide affects body weight and other clinical measures in this population. The trial is sponsored by Eli Lilly and Company and includes adults aged 18 to 55 years diagnosed with schizophrenia. Participants will be randomly assigned to receive either brenipatide or placebo, both administered by subcutaneous injection alongside their usual schizophrenia care. The study is double-blind, meaning neither participants nor researchers will know who receives the active drug or placebo. The trial consists of three periods a screening period of about one month, a treatment period lasting up to 12 months, and a follow-up period of approximately two months. During the study, participants will attend regular visits for assessments including body weight changes, cognitive testing, symptom severity scales, and functional capacity evaluations. Researchers will also monitor safety through laboratory tests and measure drug levels and immune responses. The total participation time may be up to 15 months, including screening, treatment, and follow-up to evaluate outcomes and safety comprehensively.

Age: 18Years - 55YearsAll GendersPhase 2
101 locations
E

Actively Recruiting

Researchers are evaluating the safety and tolerability of the investigational drug LTX-001 in adults aged 18 to 55 years who have schizophrenia experiencing a recent worsening of symptoms, known as an acute exacerbation. The study also aims to understand how the drug moves through the body pharmacokinetics, its early effects on schizophrenia symptoms, and changes in blood markers after taking LTX-001. Different dose levels of LTX-001 will be compared to a placebo to identify any differences in treatment effects. Eligible participants will stay in a research unit for about 35 nights, or up to 49 nights if a washout period from antipsychotic medications is needed, with three visits to the study site. During this time, they will receive oral doses of LTX-001 once or twice daily at specified amounts, or a placebo, under close monitoring. The study includes a follow-up visit one week after the overnight stay period. Participants will undergo a variety of assessments including medical history reviews, physical and neurological exams, heart electrical activity tests ECGs, blood and urine collections, and psychiatric evaluations using several standardized scales. Eye exams and brain wave recordings qEEG will also be conducted. Researchers will monitor safety through vital signs, neurological symptoms, suicidality risk, and other physical assessments from screening through day 42. The study will last about six weeks from screening to final follow-up.

Age: 18Years - 55YearsAll GendersPhase 1
10 locations
R

Actively Recruiting

Schizophrenia is a serious psychiatric condition that affects thinking, language, perception, and self-awareness. Researchers are studying an investigational oral drug called emraclidine in adults with schizophrenia to assess its safety, how it moves through the body, and its effect on disease activity. This phase 2 trial involves about 268 participants across multiple sites in the United States. Participants are divided into two parts Part A and Part B. In Part A, participants receive oral emraclidine or placebo for either 14 days or up to 21 days depending on the dosing schedule, which may include a titration period. In Part B, participants receive oral emraclidine or placebo for 42 days. Following treatment, all participants enter a 30-day safety follow-up period to monitor any adverse effects. During the study, participants attend regular visits at hospitals or clinics for medical assessments, blood tests, and side effect monitoring. Researchers also collect questionnaire data to evaluate changes in symptoms. The trial measures adverse events and detailed drug levels in the blood, along with clinical scales assessing symptom severity and improvement. Total participation lasts up to approximately 74 days, including treatment and follow-up.

Age: 18Years - 65YearsAll GendersPhase 2
7 locations
L

Actively Recruiting

Researchers are studying the long-term safety and tolerability of KarXT for treating mania or mania with mixed features in adults with Bipolar-I disorder. This phase 3 open-label extension trial focuses on participants who have either completed prior related studies or are newly diagnosed with specific criteria. The study aims to monitor adverse events and changes in symptoms over an extended period. Participants receive KarXT at specified doses, with some possibly receiving additional therapeutic doses of Lithium, Valproate, or Lamotrigine. The study does not involve placebo and is designed as a single-group intervention. The treatment and monitoring continue for up to 54 weeks, focusing on safety and symptom assessments. During the study, participants undergo regular evaluations including psychiatric assessments and safety monitoring. Researchers track treatment-emergent adverse events, serious adverse events, and changes in suicidal ideation using the Columbia-Suicide Severity Rating Scale. Additional assessments include rating scales for movement disorders and urinary symptoms. The total participation period extends up to about one year, with ongoing safety and tolerability evaluations.

Age: 18Years - 65YearsAll GendersPhase 3
184 locations
E

Actively Recruiting

Researchers are evaluating DT-101 as a potential treatment for adults with Major Depressive Disorder MDD. This study compares the effects of DT-101 to a placebo to understand how it may impact depression symptoms. The study also aims to assess the safety and tolerability of DT-101 in this population. Participants will be randomly assigned to receive one of two versions of DT-101 or a placebo. The study involves physical and neurological exams, blood and urine sample collection, and clinical assessments. Blood samples will also be analyzed to study how DT-101 is absorbed and processed by the body and to explore genetic factors that may influence response to the drug. Throughout the study, participants will attend clinic visits approximately every two weeks for health checks and to complete questionnaires about their depression. Researchers will monitor changes in depression severity using the Montgomery sberg Depression Rating Scale MADRS and other clinical measures over 42 days. Safety and ongoing suitability for participation will be regularly evaluated, with the total study duration extending up to about six weeks.

Age: 18Years - 75YearsAll GendersPhase 2
43 locations
E

Actively Recruiting

Researchers are conducting a Phase 3, randomized, double-blind, placebo-controlled study to evaluate KarXT in adults with Bipolar-I disorder experiencing acute manic or mixed episodes. The study focuses on assessing how well KarXT works compared to a placebo during a three-week inpatient treatment period. Participants must be hospitalized due to their acute symptoms, and the study includes a total duration of up to seven weeks covering screening, treatment, and safety follow-up. Participants are randomly assigned to receive either KarXT or a placebo with flexible dosing during the inpatient phase. The main goal is to observe changes in manic symptoms using the Young Mania Rating Scale over three weeks. The study monitors safety and efficacy through standardized psychiatric assessments and follows participants closely during the inpatient stay. During the trial, participants will undergo regular evaluations including psychiatric ratings and clinical global impressions to track symptom changes and treatment response. The study includes initial screening, a three-week double-blind treatment period while hospitalized, and a safety follow-up period to monitor participants health. The total participation time does not exceed seven weeks.

Age: 18Years - 65YearsAll GendersPhase 3
85 locations

1-10 of 34

1